JPH09502989A - 抗菌・抗カビ剤の経口製剤 - Google Patents
抗菌・抗カビ剤の経口製剤Info
- Publication number
- JPH09502989A JPH09502989A JP7510099A JP51009995A JPH09502989A JP H09502989 A JPH09502989 A JP H09502989A JP 7510099 A JP7510099 A JP 7510099A JP 51009995 A JP51009995 A JP 51009995A JP H09502989 A JPH09502989 A JP H09502989A
- Authority
- JP
- Japan
- Prior art keywords
- volume
- weight
- cyclodextrin
- formulation
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.抗菌・抗カビ剤、十分な量のシクロデキストリンまたはその誘導体、バルク 液体担体としての水性酸性媒体およびアルコール系共溶媒を含んでなる経口投与 用製剤。 2.1種もしくはそれ以上の薬剤学的に許容しうる甘味剤および1種もしくはそ れ以上の薬剤学的に許容しうる矯味矯臭剤をさらに含んでなる、請求の範囲第1 項に従う製剤。 3.抗菌・抗カビ剤がイトラコナゾールまたはサペルコナゾールであり、そして シクロデキストリンが0.35〜0.50の範囲内のM.S.を有し且つ1.5%よ り少ない未置換のβ−シクロデキストリンを含有するヒドロキシプロピル−β− シクロデキストリンである、請求の範囲第1または2項に従う製剤。 4.アルコール系共溶媒がプロピレングリコールである、請求の範囲第3項に従 う製剤。 5.2.0±0.1のpHを有する、請求の範囲第4項に従う製剤。 6.薬剤学的に許容しうる甘味剤が少なくとも1種の強力甘味剤および場合によ りバルク甘味剤を含んでなる、請求の範囲第5項に従う製剤。 7.強力甘味剤がサッカリン、サッカリンナトリウムまたはカルシウムよりなる 群から選択されそしてバルク甘味剤がソルビトール、マンニトール、フルクトー ス、スクロース、マルトース、グルコース、カラメルまたはハチミツよりなる群 から選択される、請求の範囲第6項に従う製剤。 8.製剤の合計容量に基づいて重量または容量により (a)4%(重量/容量)のイトラコナゾール、 (b)60%(重量/容量)のヒドロキシプロピル−β−シクロデキストリン、 (c)10%(容量/容量)のプロピレングリコール、 (d)組成物のpHを2.0±0.1の範囲内に調節するための酸および塩基、 (e)0.08%(重量/容量)のサッカリンナトリウム、 (f)1%(重量/容量)までの1種もしくはそれ以上の矯味矯臭剤、並びに (g)水 を含んでなる、請求の範囲第2項に従う製剤。 9.製剤の合計容量に基づいて重量または容量により (a)1%(重量/容量)のイトラコナゾールまたはサペルコナゾール、 (b)40%(重量/容量)のヒドロキシプロピルーβ−シクロデキストリン、 (c)10%(容量/容量)のプロピレングリコール、 (d)組成物のpHを2.0±0.1の範囲内に調節するための酸および塩基、 (e)0.06%(重量/容量)のサッカリンナトリウム、 (f)19%(容量/容量)のソルビトール(70%)非−結晶化溶液、 (g)1%(重量/容量)までの1種もしくはそれ以上の矯味矯臭剤、並びに (g)水 を含んでなる、請求の範囲第2項に従う製剤。 10.(a)活性成分をアルコール系共溶媒および酸の中に溶解させ、 (b)シクロデキストリンを水中に溶解させそしてそれに(a)で製造された溶 液を均質になるまで撹拌しながら加え、 (c)場合により、1種もしくはそれ以上の甘味剤および1種もしくはそれ以上 の矯味矯臭剤を加え、 (d)酸性度をpH2.0±0.1に調節し、そして (e)製剤を所望する最終的容量に希釈する 段階を含んでなることを特徴とする、請求の範囲第1項で請求されている製剤の 製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12950493A | 1993-09-30 | 1993-09-30 | |
US129,504 | 1993-09-30 | ||
PCT/EP1994/003169 WO1995008993A1 (en) | 1993-09-30 | 1994-09-22 | Oral formulations of an antifungal |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502989A true JPH09502989A (ja) | 1997-03-25 |
JP3034048B2 JP3034048B2 (ja) | 2000-04-17 |
Family
ID=22440301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7510099A Expired - Lifetime JP3034048B2 (ja) | 1993-09-30 | 1994-09-22 | 抗菌・抗カビ剤の経口製剤 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5707975A (ja) |
EP (1) | EP0721337B1 (ja) |
JP (1) | JP3034048B2 (ja) |
CN (1) | CN1086579C (ja) |
AP (1) | AP630A (ja) |
AT (1) | ATE209916T1 (ja) |
AU (1) | AU692180B2 (ja) |
CA (1) | CA2170622C (ja) |
CY (1) | CY2272B1 (ja) |
CZ (1) | CZ288026B6 (ja) |
DE (1) | DE69429359T2 (ja) |
DK (1) | DK0721337T3 (ja) |
ES (1) | ES2169087T3 (ja) |
FI (1) | FI115443B (ja) |
HK (1) | HK1010689A1 (ja) |
HU (1) | HU221632B1 (ja) |
IL (1) | IL111093A (ja) |
MY (1) | MY111136A (ja) |
NO (1) | NO308985B1 (ja) |
NZ (1) | NZ273619A (ja) |
OA (1) | OA10276A (ja) |
PH (1) | PH31594A (ja) |
PL (1) | PL313731A1 (ja) |
PT (1) | PT721337E (ja) |
RO (1) | RO115114B1 (ja) |
RU (1) | RU2118899C1 (ja) |
SG (1) | SG48826A1 (ja) |
SK (1) | SK282627B6 (ja) |
TW (1) | TW349870B (ja) |
WO (1) | WO1995008993A1 (ja) |
ZA (1) | ZA947619B (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69733664T3 (de) | 1996-04-19 | 2011-04-14 | Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles | Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen |
KR100883149B1 (ko) * | 1997-10-22 | 2009-02-10 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2003531099A (ja) | 1999-03-24 | 2003-10-21 | エフ エム シー コーポレーション | 改良された水溶解度をもつ医薬製剤 |
IL145661A0 (en) | 1999-03-31 | 2002-06-30 | Janssen Pharmaceutica Nv | Pregelatinized starch in a controlled release formulation |
WO2001001955A1 (en) * | 1999-07-02 | 2001-01-11 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
CA2291346A1 (en) | 1999-11-26 | 2001-05-26 | Bernard Charles Sherman | Antifungal solutions |
US6673373B2 (en) | 2001-02-01 | 2004-01-06 | Carlsbad Technology Inc. | Antifungal formulation and the methods for manufacturing and using the same |
BR0207930A (pt) * | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
CA2363376A1 (en) * | 2001-11-16 | 2003-05-16 | Bernard Charles Sherman | Solid pharmaceutical compositions for oral administration comprising itraconazole |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7446107B2 (en) * | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US7078526B2 (en) * | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
AU2003213719A1 (en) * | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
AU2003243699B2 (en) * | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
CN1255105C (zh) * | 2002-12-17 | 2006-05-10 | 上海医药工业研究院 | 齐拉西酮及其盐的水溶性包合物及其制备方法 |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
CA2440172C (en) * | 2003-09-05 | 2011-01-11 | Bernard Charles Sherman | Itraconazole solution |
US20050074494A1 (en) * | 2003-10-06 | 2005-04-07 | Xiu-Xiu Cheng | Itraconazole immediate release formulation |
US20050118265A1 (en) * | 2003-11-28 | 2005-06-02 | Anandi Krishnan | Antifungal oral dosage forms and the methods for preparation |
WO2005055952A2 (en) * | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic anti-cancer compositions |
GR1005154B (el) * | 2005-02-09 | 2006-03-13 | Verisfield (Uk) Ltd. | Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον |
JP2009502258A (ja) * | 2005-07-21 | 2009-01-29 | ノミール・メディカル・テクノロジーズ・インコーポレーテッド | 標的部位の生物学的汚染物質のレベルを下げる方法 |
WO2007047253A2 (en) * | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
TWI448285B (zh) * | 2006-07-13 | 2014-08-11 | Los Angeles Biomed Res Inst | 用以治療白黴菌症(mucormycosis)及其他真菌類疾病之組合物及方法 |
CN102114002B (zh) | 2006-12-04 | 2016-05-11 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
CA2716348C (en) | 2008-02-21 | 2017-04-04 | Sequoia Pharmaceuticals, Inc. | Diamide inhibitors of cytochrome p450 |
US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
US20100233101A1 (en) | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
KR20110139743A (ko) | 2009-03-19 | 2011-12-29 | 로스 엔젤레스 바이오메디칼 리서치 인스티튜트 엣 하버-유씨엘에이 메디칼 센터 | 모균증 및 다른 진균 질환의 치료를 위한 백신 조성물 및 방법 |
HUE028667T2 (en) * | 2010-12-16 | 2016-12-28 | Borje S Andersson | Parenteral administration of azole pharmaceutical compositions for use in treating diseases susceptible to azole compounds and methods for their preparation. |
CN102670490A (zh) * | 2012-05-10 | 2012-09-19 | 南京特丰药业股份有限公司 | 一种伊曲康唑口服溶液及其制备方法 |
CN103230363A (zh) * | 2013-03-29 | 2013-08-07 | 湖北凤凰白云山药业有限公司 | 一种抗真菌的口服溶液 |
CA3020197A1 (en) | 2017-09-01 | 2019-03-01 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
RU2707286C1 (ru) * | 2019-07-02 | 2019-11-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения |
CN114191386B (zh) * | 2021-12-26 | 2024-03-12 | 苏州海景医药科技有限公司 | 一种波生坦口服溶液的制备方法 |
CN114191387A (zh) * | 2021-12-26 | 2022-03-18 | 苏州海景医药科技有限公司 | 一种伏立康唑口服液的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61500788A (ja) * | 1983-12-21 | 1986-04-24 | ヤンセン・フア−マセウテイカ・エヌ・ヴエ− | 水に不安定なまたは僅かに溶解性の薬物を含有する医薬調製物およびその製造方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4863737A (en) * | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
US4883785A (en) * | 1984-07-27 | 1989-11-28 | Chow Wing Sun | Complex of anti-fungal agent and cyclodextrin and method |
US4870060A (en) * | 1985-03-15 | 1989-09-26 | Janssen Pharmaceutica | Derivatives of γ-cylodextrin |
GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
ES2033086T3 (es) * | 1988-01-29 | 1993-03-01 | Sankyo Company Limited | Un procedimiento para la preparacion de una composicion farmaceutica. |
ATE201408T1 (de) * | 1992-03-18 | 2001-06-15 | Janssen Pharmaceutica Nv | Itraconazol- und saperconazolstereoisomere |
-
1994
- 1994-09-08 TW TW083108274A patent/TW349870B/zh not_active IP Right Cessation
- 1994-09-08 PH PH48937A patent/PH31594A/en unknown
- 1994-09-22 JP JP7510099A patent/JP3034048B2/ja not_active Expired - Lifetime
- 1994-09-22 SG SG1996002179A patent/SG48826A1/en unknown
- 1994-09-22 PT PT94927639T patent/PT721337E/pt unknown
- 1994-09-22 CA CA002170622A patent/CA2170622C/en not_active Expired - Lifetime
- 1994-09-22 NZ NZ273619A patent/NZ273619A/en not_active IP Right Cessation
- 1994-09-22 RU RU96108776A patent/RU2118899C1/ru active
- 1994-09-22 PL PL94313731A patent/PL313731A1/xx unknown
- 1994-09-22 CN CN94193602A patent/CN1086579C/zh not_active Expired - Lifetime
- 1994-09-22 EP EP94927639A patent/EP0721337B1/en not_active Expired - Lifetime
- 1994-09-22 WO PCT/EP1994/003169 patent/WO1995008993A1/en active IP Right Grant
- 1994-09-22 CZ CZ1996823A patent/CZ288026B6/cs not_active IP Right Cessation
- 1994-09-22 DK DK94927639T patent/DK0721337T3/da active
- 1994-09-22 SK SK399-96A patent/SK282627B6/sk not_active IP Right Cessation
- 1994-09-22 US US08/604,950 patent/US5707975A/en not_active Expired - Lifetime
- 1994-09-22 AT AT94927639T patent/ATE209916T1/de active
- 1994-09-22 DE DE69429359T patent/DE69429359T2/de not_active Expired - Lifetime
- 1994-09-22 RO RO96-00673A patent/RO115114B1/ro unknown
- 1994-09-22 AP APAP/P/1996/000792A patent/AP630A/en active
- 1994-09-22 HU HU9600804A patent/HU221632B1/hu unknown
- 1994-09-22 AU AU76979/94A patent/AU692180B2/en not_active Expired
- 1994-09-22 ES ES94927639T patent/ES2169087T3/es not_active Expired - Lifetime
- 1994-09-28 MY MYPI94002583A patent/MY111136A/en unknown
- 1994-09-29 ZA ZA947619A patent/ZA947619B/xx unknown
- 1994-09-29 IL IL11109394A patent/IL111093A/en not_active IP Right Cessation
-
1996
- 1996-03-27 NO NO961233A patent/NO308985B1/no not_active IP Right Cessation
- 1996-03-29 FI FI961436A patent/FI115443B/fi not_active IP Right Cessation
- 1996-03-29 OA OA60806A patent/OA10276A/en unknown
-
1998
- 1998-10-27 HK HK98111559A patent/HK1010689A1/xx not_active IP Right Cessation
-
2002
- 2002-05-15 CY CY0200025A patent/CY2272B1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61500788A (ja) * | 1983-12-21 | 1986-04-24 | ヤンセン・フア−マセウテイカ・エヌ・ヴエ− | 水に不安定なまたは僅かに溶解性の薬物を含有する医薬調製物およびその製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3034048B2 (ja) | 抗菌・抗カビ剤の経口製剤 | |
EP0759741B1 (en) | Mucoadhesive emulsions containing cyclodextrin | |
US6407079B1 (en) | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | |
AU565966B2 (en) | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | |
CA2405072C (en) | Gel compositions containing metronidazole | |
EP1267941B1 (en) | Alprazolam inclusion complexes and pharmaceutical compositions thereof | |
RU96108776A (ru) | Преоральные противогрибковые композиции | |
JP2000513029A (ja) | ボリコナゾールを含有する薬剤製剤 | |
US6077871A (en) | Droloxifene pharmaceutical compositions | |
WO2001001955A1 (en) | Nasal formulation of an antifungal | |
ES2780363T3 (es) | Complejos de inclusión de voriconazol | |
CA2189863C (en) | Mucoadhesive emulsions containing cyclodextrin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080218 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090218 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100218 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100218 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110218 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120218 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120218 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130218 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130218 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140218 Year of fee payment: 14 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |